In vitro manogepix susceptibility testing of South African Emergomyces africanus, Emergomyces pasteurianus, and Blastomyces emzantsi clinical isolates
- PMID: 37971237
- PMCID: PMC10720492
- DOI: 10.1128/aac.01104-23
In vitro manogepix susceptibility testing of South African Emergomyces africanus, Emergomyces pasteurianus, and Blastomyces emzantsi clinical isolates
Abstract
We performed in vitro antifungal susceptibility testing of manogepix against the yeast phase of 78 Emergomyces africanus, 2 Emergomyces pasteurianus, and 5 Blastomyces emzantsi isolates using a reference broth microdilution method following Clinical and Laboratory Standards Institute recommendations. All three pathogens had low minimum inhibitory concentrations ranging from <0.0005 to 0.008 mg/L. Manogepix should be investigated in animal models and potentially in future human clinical trials for endemic mycoses.
Keywords: APX001A; antifungal susceptibility testing; blastomycosis; emergomycosis; manogepix; thermally dimorphic fungi.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- Kenyon C, Bonorchis K, Corcoran C, Meintjes G, Locketz M, Lehloenya R, Vismer HF, Naicker P, Prozesky H, van Wyk M, Bamford C, du Plooy M, Imrie G, Dlamini S, Borman AM, Colebunders R, Yansouni CP, Mendelson M, Govender NP. 2013. A dimorphic fungus causing disseminated infection in South Africa. N Engl J Med 369:1416–1424. doi: 10.1056/NEJMoa1215460 - DOI - PubMed
-
- Thompson GR, Le T, Chindamporn A, Kauffman CA, Alastruey-Izquierdo A, Ampel NM, Andes DR, Armstrong-James D, Ayanlowo O, Baddley JW, et al. 2021. Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of medical mycology in cooperation with the International society for human and animal mycology. Lancet Infect Dis 21:e364–e374. doi: 10.1016/S1473-3099(21)00191-2 - DOI - PMC - PubMed
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
